Latest Period
Q1 2026
Security Snapshot
NeuroSense Therapeutics Ltd. - ORDINARY SHARES (NRSN) Institutional Ownership
CUSIP: M74240108
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
13
Shares (Excl. Options)
379,710
Price
$0.76
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / ORDINARY SHARES
- Symbol
- NRSN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 379,710
- Total 13F value
- $286,654
- Portfolio coverage rank
- 0%
- Share change
- +33,576
- Value change
- +$24,591
- Number of holders
- 13
- SEC-reported price per share
- $0.83
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
1 identity field
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NRSN - NeuroSense Therapeutics Ltd. - ORDINARY SHARES is tracked under CUSIP M74240108.
- 13 institutions reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 13 to 13 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $266,180 to $286,654.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 13 institutions filings for Q1 2026.
Security key
M74240108
Latest holder period
Q1 2026
13F holders
13
13D/G owners
0
CIK / CUSIP context first
Open Q1 2026 holders
NRSN full holder history
NeuroSense Therapeutics Ltd. SEC filings
NeuroSense Therapeutics Ltd. company facts
NeuroSense Therapeutics Ltd. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP M74240108:
As of 31 Mar 2026, 13 institutional investors reported holding 379,710 shares of NeuroSense Therapeutics Ltd. - ORDINARY SHARES (NRSN).
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Latest
Q1 2026
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 379,710 | $286,654 | +$24,591 | $0.76 | 13 |
| 2025 Q4 | 346,134 | $266,180 | +$20,285 | $0.77 | 13 |
| 2025 Q3 | 277,925 | $346,797 | -$459,778 | $1.25 | 10 |
| 2025 Q2 | 510,044 | $964,359 | +$526,601 | $1.89 | 17 |
| 2025 Q1 | 194,892 | $180,778 | -$528,472 | $0.93 | 11 |
| 2024 Q4 | 646,513 | $775,846 | +$499,456 | $1.20 | 13 |
| 2024 Q3 | 225,356 | $285,899 | -$1,598,380 | $1.27 | 7 |
| 2024 Q2 | 1,671,167 | $1,871,586 | +$1,613,102 | $1.12 | 7 |
| 2024 Q1 | 167,126 | $303,946 | +$74,376 | $1.82 | 8 |
| 2023 Q4 | 141,595 | $110,566 | -$461,459 | $0.78 | 8 |
| 2023 Q3 | 779,367 | $554,109 | -$580,781 | $0.71 | 5 |
| 2023 Q2 | 1,474,496 | $2,196,470 | +$2,008,420 | $1.49 | 6 |
| 2023 Q1 | 123,812 | $243,354 | +$193,107 | $1.74 | 5 |
| 2022 Q4 | 34,694 | $41,618 | -$46,588 | $1.22 | 5 |
| 2022 Q3 | 73,659 | $132,000 | -$515,971 | $1.80 | 4 |
| 2022 Q2 | 217,265 | $733,000 | +$65,709 | $3.37 | 7 |
| 2022 Q1 | 168,852 | $694,000 | +$264,799 | $3.94 | 7 |
| 2021 Q4 | 154,961 | $380,000 | +$380,000 | $2.45 | 5 |